Intrinsic value of Dermira - DERM

Previous Close

$26.18

  Intrinsic Value

$1.46

stock screener

  Rating & Target

str. sell

-94%

Previous close

$26.18

 
Intrinsic value

$1.46

 
Up/down potential

-94%

 
Rating

str. sell

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of DERM stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

Please visit our new site that uses elements of artificial intelligence for stock valuation: artificial intelligence value of Dermira (DERM) stock.

STOCK VALUATION INPUT DATA

Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Shares outstanding, mln

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  228.57
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  23
  37
  57
  85
  123
  174
  239
  321
  422
  543
  685
  851
  1,041
  1,254
  1,492
  1,755
  2,041
  2,351
  2,685
  3,041
  3,418
  3,818
  4,239
  4,680
  5,142
  5,625
  6,128
  6,653
  7,198
  7,765
  8,354
Variable operating expenses, $m
 
  91
  141
  210
  305
  431
  592
  795
  1,043
  1,343
  1,696
  2,106
  2,574
  3,103
  3,692
  4,341
  5,049
  5,817
  6,641
  7,521
  8,456
  9,444
  10,485
  11,577
  12,720
  13,914
  15,159
  16,456
  17,805
  19,208
  20,666
Fixed operating expenses, $m
 
  74
  76
  78
  79
  81
  83
  86
  88
  90
  92
  94
  97
  99
  102
  104
  107
  110
  112
  115
  118
  121
  124
  127
  130
  133
  137
  140
  144
  147
  151
Total operating expenses, $m
  113
  165
  217
  288
  384
  512
  675
  881
  1,131
  1,433
  1,788
  2,200
  2,671
  3,202
  3,794
  4,445
  5,156
  5,927
  6,753
  7,636
  8,574
  9,565
  10,609
  11,704
  12,850
  14,047
  15,296
  16,596
  17,949
  19,355
  20,817
Operating income, $m
  -91
  -128
  -160
  -203
  -261
  -338
  -436
  -559
  -709
  -890
  -1,102
  -1,349
  -1,630
  -1,948
  -2,301
  -2,690
  -3,115
  -3,575
  -4,069
  -4,596
  -5,156
  -5,747
  -6,370
  -7,024
  -7,708
  -8,423
  -9,168
  -9,944
  -10,751
  -11,590
  -12,462
EBITDA, $m
  -91
  -128
  -159
  -202
  -260
  -337
  -435
  -557
  -707
  -886
  -1,098
  -1,343
  -1,624
  -1,940
  -2,291
  -2,679
  -3,102
  -3,559
  -4,051
  -4,576
  -5,133
  -5,722
  -6,343
  -6,993
  -7,675
  -8,386
  -9,128
  -9,900
  -10,704
  -11,540
  -12,408
Interest expense (income), $m
  0
  0
  1
  2
  5
  8
  12
  18
  25
  33
  43
  55
  69
  85
  102
  122
  144
  168
  194
  222
  252
  283
  317
  352
  389
  427
  468
  510
  554
  599
  646
Earnings before tax, $m
  -89
  -128
  -160
  -205
  -266
  -346
  -448
  -577
  -734
  -923
  -1,145
  -1,404
  -1,699
  -2,032
  -2,404
  -2,813
  -3,259
  -3,743
  -4,263
  -4,818
  -5,407
  -6,031
  -6,687
  -7,376
  -8,097
  -8,850
  -9,636
  -10,453
  -11,304
  -12,189
  -13,109
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -89
  -128
  -160
  -205
  -266
  -346
  -448
  -577
  -734
  -923
  -1,145
  -1,404
  -1,699
  -2,032
  -2,404
  -2,813
  -3,259
  -3,743
  -4,263
  -4,818
  -5,407
  -6,031
  -6,687
  -7,376
  -8,097
  -8,850
  -9,636
  -10,453
  -11,304
  -12,189
  -13,109

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  252
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  313
  98
  151
  226
  327
  462
  635
  852
  1,119
  1,440
  1,818
  2,258
  2,760
  3,327
  3,959
  4,655
  5,415
  6,237
  7,121
  8,065
  9,067
  10,127
  11,243
  12,414
  13,640
  14,920
  16,255
  17,646
  19,093
  20,597
  22,160
Adjusted assets (=assets-cash), $m
  61
  98
  151
  226
  327
  462
  635
  852
  1,119
  1,440
  1,818
  2,258
  2,760
  3,327
  3,959
  4,655
  5,415
  6,237
  7,121
  8,065
  9,067
  10,127
  11,243
  12,414
  13,640
  14,920
  16,255
  17,646
  19,093
  20,597
  22,160
Revenue / Adjusted assets
  0.377
  0.378
  0.377
  0.376
  0.376
  0.377
  0.376
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
Average production assets, $m
  2
  2
  4
  6
  8
  11
  16
  21
  27
  35
  45
  55
  68
  82
  97
  114
  133
  153
  175
  198
  222
  248
  276
  304
  334
  366
  398
  432
  468
  505
  543
Working capital, $m
  249
  -5
  -7
  -11
  -16
  -23
  -31
  -42
  -55
  -71
  -89
  -111
  -135
  -163
  -194
  -228
  -265
  -306
  -349
  -395
  -444
  -496
  -551
  -608
  -668
  -731
  -797
  -865
  -936
  -1,009
  -1,086
Total debt, $m
  0
  22
  70
  137
  229
  350
  505
  701
  941
  1,230
  1,570
  1,966
  2,418
  2,928
  3,497
  4,123
  4,807
  5,547
  6,343
  7,193
  8,095
  9,048
  10,053
  11,107
  12,210
  13,362
  14,564
  15,815
  17,117
  18,471
  19,878
Total liabilities, $m
  65
  88
  136
  203
  295
  416
  571
  767
  1,007
  1,296
  1,636
  2,032
  2,484
  2,994
  3,563
  4,189
  4,873
  5,613
  6,409
  7,259
  8,161
  9,114
  10,119
  11,173
  12,276
  13,428
  14,630
  15,881
  17,183
  18,537
  19,944
Total equity, $m
  247
  10
  15
  23
  33
  46
  63
  85
  112
  144
  182
  226
  276
  333
  396
  465
  541
  624
  712
  807
  907
  1,013
  1,124
  1,241
  1,364
  1,492
  1,626
  1,765
  1,909
  2,060
  2,216
Total liabilities and equity, $m
  312
  98
  151
  226
  328
  462
  634
  852
  1,119
  1,440
  1,818
  2,258
  2,760
  3,327
  3,959
  4,654
  5,414
  6,237
  7,121
  8,066
  9,068
  10,127
  11,243
  12,414
  13,640
  14,920
  16,256
  17,646
  19,092
  20,597
  22,160
Debt-to-equity ratio
  0.000
  2.240
  4.620
  6.070
  6.980
  7.570
  7.960
  8.230
  8.410
  8.540
  8.640
  8.710
  8.760
  8.800
  8.830
  8.860
  8.880
  8.890
  8.910
  8.920
  8.930
  8.930
  8.940
  8.950
  8.950
  8.960
  8.960
  8.960
  8.970
  8.970
  8.970
Adjusted equity ratio
  -0.082
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -89
  -128
  -160
  -205
  -266
  -346
  -448
  -577
  -734
  -923
  -1,145
  -1,404
  -1,699
  -2,032
  -2,404
  -2,813
  -3,259
  -3,743
  -4,263
  -4,818
  -5,407
  -6,031
  -6,687
  -7,376
  -8,097
  -8,850
  -9,636
  -10,453
  -11,304
  -12,189
  -13,109
Depreciation, amort., depletion, $m
  0
  0
  0
  1
  1
  1
  2
  2
  3
  4
  5
  6
  7
  8
  10
  11
  13
  15
  17
  20
  22
  25
  28
  30
  33
  37
  40
  43
  47
  50
  54
Funds from operations, $m
  -73
  -128
  -160
  -205
  -265
  -345
  -447
  -575
  -731
  -919
  -1,141
  -1,398
  -1,692
  -2,024
  -2,394
  -2,801
  -3,246
  -3,728
  -4,245
  -4,798
  -5,385
  -6,006
  -6,659
  -7,345
  -8,063
  -8,814
  -9,596
  -10,410
  -11,258
  -12,139
  -13,055
Change in working capital, $m
  1
  -2
  -3
  -4
  -5
  -7
  -8
  -11
  -13
  -16
  -19
  -22
  -25
  -28
  -31
  -34
  -37
  -40
  -43
  -46
  -49
  -52
  -55
  -57
  -60
  -63
  -65
  -68
  -71
  -74
  -77
Cash from operations, $m
  -74
  -126
  -157
  -201
  -260
  -338
  -438
  -564
  -718
  -903
  -1,122
  -1,377
  -1,668
  -1,996
  -2,363
  -2,767
  -3,209
  -3,687
  -4,202
  -4,752
  -5,336
  -5,954
  -6,605
  -7,288
  -8,003
  -8,751
  -9,530
  -10,342
  -11,187
  -12,065
  -12,978
Maintenance CAPEX, $m
  0
  0
  0
  0
  -1
  -1
  -1
  -2
  -2
  -3
  -4
  -4
  -6
  -7
  -8
  -10
  -11
  -13
  -15
  -17
  -20
  -22
  -25
  -28
  -30
  -33
  -37
  -40
  -43
  -47
  -50
New CAPEX, $m
  -1
  -1
  -1
  -2
  -2
  -3
  -4
  -5
  -7
  -8
  -9
  -11
  -12
  -14
  -15
  -17
  -19
  -20
  -22
  -23
  -25
  -26
  -27
  -29
  -30
  -31
  -33
  -34
  -35
  -37
  -38
Cash from investing activities, $m
  -130
  -1
  -1
  -2
  -3
  -4
  -5
  -7
  -9
  -11
  -13
  -15
  -18
  -21
  -23
  -27
  -30
  -33
  -37
  -40
  -45
  -48
  -52
  -57
  -60
  -64
  -70
  -74
  -78
  -84
  -88
Free cash flow, $m
  -204
  -127
  -159
  -203
  -263
  -342
  -444
  -571
  -727
  -914
  -1,135
  -1,392
  -1,686
  -2,017
  -2,387
  -2,794
  -3,239
  -3,721
  -4,239
  -4,792
  -5,380
  -6,002
  -6,657
  -7,344
  -8,064
  -8,816
  -9,600
  -10,416
  -11,265
  -12,149
  -13,067
Issuance/(repayment) of debt, $m
  0
  22
  48
  67
  92
  121
  156
  196
  240
  289
  341
  396
  452
  510
  568
  626
  684
  740
  796
  850
  902
  954
  1,004
  1,054
  1,103
  1,152
  1,202
  1,251
  1,302
  1,354
  1,407
Issuance/(repurchase) of shares, $m
  139
  143
  166
  213
  276
  360
  466
  598
  761
  955
  1,183
  1,448
  1,749
  2,089
  2,467
  2,882
  3,335
  3,825
  4,351
  4,912
  5,508
  6,137
  6,798
  7,493
  8,219
  8,978
  9,769
  10,593
  11,449
  12,340
  13,265
Cash from financing (excl. dividends), $m  
  139
  165
  214
  280
  368
  481
  622
  794
  1,001
  1,244
  1,524
  1,844
  2,201
  2,599
  3,035
  3,508
  4,019
  4,565
  5,147
  5,762
  6,410
  7,091
  7,802
  8,547
  9,322
  10,130
  10,971
  11,844
  12,751
  13,694
  14,672
Total cash flow (excl. dividends), $m
  -65
  38
  55
  77
  105
  138
  178
  223
  274
  330
  389
  451
  516
  582
  649
  715
  780
  845
  908
  969
  1,029
  1,088
  1,146
  1,203
  1,259
  1,315
  1,371
  1,428
  1,486
  1,545
  1,606
Retained Cash Flow (-), $m
  -62
  -143
  -166
  -213
  -276
  -360
  -466
  -598
  -761
  -955
  -1,183
  -1,448
  -1,749
  -2,089
  -2,467
  -2,882
  -3,335
  -3,825
  -4,351
  -4,912
  -5,508
  -6,137
  -6,798
  -7,493
  -8,219
  -8,978
  -9,769
  -10,593
  -11,449
  -12,340
  -13,265
Prev. year cash balance distribution, $m
 
  252
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  147
  -111
  -136
  -172
  -221
  -288
  -375
  -487
  -625
  -794
  -996
  -1,233
  -1,507
  -1,818
  -2,168
  -2,555
  -2,980
  -3,443
  -3,943
  -4,478
  -5,048
  -5,653
  -6,290
  -6,961
  -7,663
  -8,398
  -9,165
  -9,964
  -10,795
  -11,660
Discount rate, %
 
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
 
  141
  -102
  -118
  -141
  -172
  -209
  -253
  -304
  -359
  -416
  -473
  -526
  -573
  -610
  -636
  -649
  -649
  -634
  -607
  -569
  -522
  -469
  -412
  -355
  -298
  -245
  -197
  -154
  -118
  -88
Current shareholders' claim on cash, %
  100
  50.0
  10.4
  2.5
  0.7
  0.2
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Dermira, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil. Cimzia is an injectable biologic tumor necrosis factor-alpha inhibitor, or TNF inhibitor that is approved and marketed for the treatment of numerous inflammatory diseases spanning multiple medical specialties, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease, in multiple countries, including the United States. Glycopyrronium tosylate is a small molecule anticholinergic product for topical application for the treatment of primary axillary hyperhidrosis. Olumacostat glasaretil is a small molecule that targets sebum production following topical application for the treatment of acne.

FINANCIAL RATIOS  of  Dermira (DERM)

Valuation Ratios
P/E Ratio -10.5
Price to Sales 40.6
Price to Book 3.8
Price to Tangible Book
Price to Cash Flow -12.6
Price to Free Cash Flow -12.4
Growth Rates
Sales Growth Rate 228.6%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate NaN%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets -33.3%
Ret/ On Assets - 3 Yr. Avg. -34.5%
Return On Total Capital -41.2%
Ret/ On T. Cap. - 3 Yr. Avg. -41.7%
Return On Equity -41.2%
Return On Equity - 3 Yr. Avg. -42.1%
Asset Turnover 0.1
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin -387%
EBITDA Margin - 3 Yr. Avg. -657.6%
Operating Margin -391.3%
Oper. Margin - 3 Yr. Avg. -663.8%
Pre-Tax Margin -387%
Pre-Tax Margin - 3 Yr. Avg. -657.6%
Net Profit Margin -387%
Net Profit Margin - 3 Yr. Avg. -652.8%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0.4%
Payout Ratio 0%

DERM stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the DERM stock intrinsic value calculation we used $23 million for the last fiscal year's total revenue generated by Dermira. The default revenue input number comes from 2016 income statement of Dermira. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our DERM stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for DERM is calculated based on our internal credit rating of Dermira, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Dermira.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of DERM stock the variable cost ratio is equal to 247.8%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $72 million in the base year in the intrinsic value calculation for DERM stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 3.5% for Dermira.

Corporate tax rate of 27% is the nominal tax rate for Dermira. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the DERM stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for DERM are equal to 6.5%.

Life of production assets of 10 years is the average useful life of capital assets used in Dermira operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for DERM is equal to -13%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $247 million for Dermira - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 42.071 million for Dermira is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Dermira at the current share price and the inputted number of shares is $1.1 billion.

RELATED COMPANIES Price Int.Val. Rating
ABBV AbbVie 118.75 30.60  str.sell
GSK GlaxoSmithKlin 36.84 42.07  hold
MRK Merck&Co 54.87 30.23  sell
LLY Eli Lilly 78.75 111.38  buy
JNJ Johnson&Johnso 132.02 146.14  hold

COMPANY NEWS

▶ Dermira reports 4Q loss   [Feb-23-18 05:00AM  Associated Press]
▶ ETFs with exposure to Dermira, Inc. : December 28, 2017   [Dec-28-17 12:02PM  Capital Cube]
▶ Dermira Inc (DERM): What Are The Future Prospects?   [Nov-28-17 04:26PM  Simply Wall St.]
▶ Dermira reports 3Q loss   [Nov-06-17 04:49PM  Associated Press]
▶ Is It The Right Time To Buy Dermira Inc (DERM)?   [Sep-08-17 08:20PM  Simply Wall St.]
▶ Dermira reports 2Q loss   [Aug-07-17 10:48PM  Associated Press]
▶ ETFs with exposure to Dermira, Inc. : July 24, 2017   [Jul-24-17 03:21PM  Capital Cube]
▶ ETFs with exposure to Dermira, Inc. : July 14, 2017   [Jul-14-17 01:55PM  Capital Cube]
▶ Teva Pharma, Eagle Pharma, Depomed Among Slew Getting Price Haircuts   [May-25-17 04:10PM  Investor's Business Daily]
▶ Biotech And Pharma Industry And Stock News   [01:38PM  Investor's Business Daily]
▶ Dermira reports 1Q loss   [May-08-17 05:34PM  Associated Press]
▶ Xenon Pharma Dumps Acne Drug After Study Failure   [Mar-24-17 09:00AM  Investopedia]
▶ Dermira Psoriasis Drug Cimzia Did Well In Study   [Jan-19-17 01:10PM  at Investopedia]
Financial statements of DERM
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.